{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T13:02:28Z","timestamp":1772542948310,"version":"3.50.1"},"reference-count":78,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Ther. Deliv."],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.4155\/tde-2021-0021","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T10:46:51Z","timestamp":1621421211000},"page":"477-488","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Oral Insulin Delivery: Utopia, Currently Possible or a Near Reality?"],"prefix":"10.1080","volume":"12","author":[{"given":"Rute","family":"Pinelo","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, Lisboa1649003, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3814-1533","authenticated-orcid":false,"given":"Lu\u00eds","family":"Roque","sequence":"additional","affiliation":[{"name":"iMED.ULisboa (Research Institute for Medicines), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, Lisboa1649003, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1046-4031","authenticated-orcid":false,"given":"Catarina Pinto","family":"Reis","sequence":"additional","affiliation":[{"name":"iMED.ULisboa (Research Institute for Medicines), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, Lisboa1649003, Portugal"},{"name":"IBEB (Biophysics & Biomedical Engineering), Faculty of Sciences, Universidade de Lisboa, Campo Grande, Lisboa1749016, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"key":"e_1_3_2_3_1","volume-title":"IDF Diabetes Atlas (8th Edition).","author":"International Diabetes Federation","year":"2017","unstructured":"International Diabetes Federation . IDF Diabetes Atlas (8th Edition).International Diabetes Federation, Brussels, Belgium (2017)."},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.22159\/ijap.2019v11i2.31338"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.4103\/2230-973X.176456"},{"key":"e_1_3_2_6_1","unstructured":"Food and Drug Administration (FDA) . Afrezza\u00ae (insulin human) inhalation powder. www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/022472Orig1s000TOC.cfm"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.5603\/EP.2016.0044"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-015-0136-y"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12607"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717540801905165"},{"key":"e_1_3_2_11_1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1201\/9780429197833-12","volume-title":"Controlled Drug Delivery Systems.","author":"Jost A","year":"2020","unstructured":"Jost A , AnikeM , OparaE. New developments in oral insulin delivery. In: Controlled Drug Delivery Systems.CRC Press, FL, USA, 199\u2013219 (2020)."},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.23736\/S0391-1977.19.03055-4"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/children7120307"},{"key":"e_1_3_2_14_1","volume-title":"Pharmaceutical Nanotechnology: Innovation and Production","author":"de van Voorde MH","year":"2017","unstructured":"de van Voorde MH , CornierJ , KwadeA , OwenA. Pharmaceutical Nanotechnology: Innovation and Production. Wiley-VCH Verlag GmbH & Co. KGaA, FL, USA (2017)."},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom10050675"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21347"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-020-00652-z"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12852"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-10939-8_3"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.04.012"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1722338115"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2017.11.012"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.4155\/ppa-2017-0041"},{"key":"e_1_3_2_24_1","unstructured":"World Health Organization (WHO) . The top 10 causes of death. www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death"},{"key":"e_1_3_2_25_1","volume-title":"IDF Diabetes Atlas (9th Edition).","author":"International Diabetes Federation","year":"2019","unstructured":"International Diabetes Federation . IDF Diabetes Atlas (9th Edition).International Diabetes Federation, Brussels, Belgium (2019)."},{"key":"e_1_3_2_26_1","unstructured":"World Health Organization (WHO) . Coronavirus Disease (Covid-19) Dashboard. https:\/\/covid19.who.int\/"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01580.x"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674379403900207"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12957"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12175"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2019.2505"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-015-0326-3"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2006.12.022"},{"key":"e_1_3_2_34_1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1201\/9780429197833-12","volume-title":"Controlled Drug Delivery Systems.","author":"Jost A","year":"2020","unstructured":"Jost A , AnikeM , OparaE. New developments in oral insulin delivery. In: Controlled Drug Delivery Systems.CRC Press, FL, USA, 199\u2013219 (2020)."},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-47720-8.00015-8"},{"key":"e_1_3_2_36_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-3-030-29207-2","volume-title":"Nanoscience in Medicine Vol.1.","author":"Daima HK","year":"2020","unstructured":"Daima HK , PNN , RanjanS , DasguptaN , LichtfouseE. Advanced nanostructures for oral insulin delivery. In: Nanoscience in Medicine Vol.1.Springer International Publishing,Switzerland, 187\u2013212 (2020)."},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.4155\/TDE.15.47"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11020078"},{"key":"e_1_3_2_39_1","unstructured":"National Library of Medicine (NLM) . A two part study of peroral insulin in Type 2 diabetes. www.clinicaltrials.gov\/ct2\/show\/record\/NCT00990444?term=Ora+2&draw=2&rank=2&view=record"},{"key":"e_1_3_2_40_1","unstructured":"National Library of Medicine (NLM) . A study to determine the absorption of peroral insulin in dextran matrix (ORA3). www.clinicaltrials.gov\/ct2\/show\/NCT01114750?term=%22oral+insulin%22&draw=5&rank=32"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2018.11.010"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2016.02.004"},{"key":"e_1_3_2_43_1","unstructured":"Chinese Clinical Trial Registry (ChiCTR) . ChiCTR-TRC-12001872 version V1.3. www.chictr.org.cn\/hvshowproject.aspx?id=2042"},{"key":"e_1_3_2_44_1","unstructured":"National Library of Medicine (NLM) . Efficacy safety and tolerability of multiple doses of Oshadi Icp (Oshadi oral insulin) in patients with Type 1 diabetes mellitus:Phase II clinical study. www.clinicaltrials.gov\/ct2\/show\/record\/NCT01973920?term=%22oral+insulin%22&draw=2&rank=9"},{"issue":"4","key":"e_1_3_2_45_1","first-page":"373","article-title":"History of diabetes mellitus","volume":"23","author":"Ahmed AM","year":"2002","unstructured":"Ahmed AM . History of diabetes mellitus. Saudi Med. J.23(4), 373\u2013378 (2002).","journal-title":"Saudi Med. J."},{"key":"e_1_3_2_46_1","unstructured":"National Library of Medicine (NLM) . A trial investigating the safety tolerability pharmacokinetics and pharmacodynamics of NNC0148-0000-0362 in healthy subjects. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01597713"},{"key":"e_1_3_2_47_1","unstructured":"Adis Insight . NN 1952. https:\/\/adisinsight.springer.com\/drugs\/800031364"},{"key":"e_1_3_2_48_1","unstructured":"Adis Insight . Insulin 320. https:\/\/adisinsight.springer.com\/drugs\/800042743"},{"key":"e_1_3_2_49_1","unstructured":"National Library of Medicine (NLM) . A trial investigating the safety tolerability pharmacokinetics and pharmacodynamics of insulin 320 in healthy subjects. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02479022?term=NCT02479022&rank=1"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30372-3"},{"key":"e_1_3_2_51_1","unstructured":"National Library of Medicine (NLM) . Trial to compare NNC0123-0000-0338 in a tablet formulation and insulin glargine in subjects with Type 2 diabetes currently treated with oral antidiabetic therapy. www.clinicaltrials.gov\/ct2\/show\/NCT02470039?term=%22oral+insulin%22&draw=5&rank=33"},{"key":"e_1_3_2_52_1","unstructured":"Adis Insight . Insulin 338. https:\/\/adisinsight.springer.com\/drugs\/800034087"},{"key":"e_1_3_2_53_1","unstructured":"Adis Insight . Insulin icodec - Novo Nordisk. https:\/\/adisinsight.springer.com\/drugs\/800037853"},{"key":"e_1_3_2_54_1","unstructured":"National Library of Medicine (NLM) . A research study of how different amounts of a new medicine NNC0148-0287 C (insulin 287) works on the blood sugar of people who are Japanese with Type 1 diabetes when given once a week. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03766854?term=NCT03766854&rank=1"},{"key":"e_1_3_2_55_1","unstructured":"National Library of Medicine (NLM) . A research study to compare two types of insulin a new insulin insulin icodec and an available insulin insulin glargine in people with Type 2 diabetes. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04460885?term=NCT04460885&rank=1"},{"key":"e_1_3_2_56_1","unstructured":"Adis Insight . HDV Insulin \u2013 Diasome Pharmaceuticals. https:\/\/adisinsight.springer.com\/drugs\/800028110"},{"key":"e_1_3_2_57_1","unstructured":"Diasome Pharmaceuticals . Breakthrough HDV Technology. www.diasome.com\/breakthrough-hdv-technology"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.2337\/db20-111-LB"},{"key":"e_1_3_2_59_1","unstructured":"National Library of Medicine (NLM) . Comparison of Pharmacokinetics safety tolerability and pharmacodynamics of biocon insulin tregopil and insulin aspart. www.clinicaltrials.gov\/ct2\/show\/NCT04141423?term=%22oral+insulin%22&draw=4&rank=28"},{"key":"e_1_3_2_60_1","unstructured":"National Library of Medicine (NLM) . Comparison of insulin tregopil (IN-105) with insulin aspart in Type 2 diabetes mellitus patients. www.clinicaltrials.gov\/ct2\/show\/study\/NCT03430856?term=%22oral+insulin%22&draw=4&rank=29"},{"key":"e_1_3_2_61_1","unstructured":"Adis Insight . Insulin tregopil \u2013 Biocon. https:\/\/adisinsight.springer.com\/drugs\/800015167"},{"key":"e_1_3_2_62_1","unstructured":"Oramed Pharmaceuticals . Oramed initiates Phase III trial of oral insulin. www.oramed.com\/oramed-initiates-phase-3-trial-of-oral-insulin\/"},{"key":"e_1_3_2_63_1","unstructured":"National Library of Medicine (NLM) . A study to compare ORMD-0801 once daily to ORMD-0801 three times daily in subjects with Type 1 diabetes. www.clinicaltrials.gov\/ct2\/show\/NCT04150107?term=%22oral+insulin%22&draw=3&rank=20"},{"key":"e_1_3_2_64_1","unstructured":"National Library of Medicine (NLM) . A study to evaluate the effect of ORMD-0801 in patients with Type 2 diabetes mellitus. www.clinicaltrials.gov\/ct2\/show\/NCT04564846?term=%22oral+insulin%22&draw=4&rank=23"},{"key":"e_1_3_2_65_1","unstructured":"National Library of Medicine (NLM) . Study to evaluate the efficacy and safety of ORMD-0801 in subjects with Type 2 diabetes mellitus. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04606576?term=oral%insulin&lupd_s=01%2F12%2F2020&lupd_e=04%2F02%2F2022&draw=3&rank=12"},{"key":"e_1_3_2_66_1","unstructured":"Adis Insight . Insulin oral \u2013 Apollo Life Sciences. https:\/\/adisinsight.springer.com\/drugs\/800025338"},{"key":"e_1_3_2_67_1","unstructured":"Adis Insight . Insulin oral \u2013 Provalis. https:\/\/adisinsight.springer.com\/drugs\/800007555"},{"key":"e_1_3_2_68_1","unstructured":"Adis Insight . Research programme: insulin oral \u2013 Abeona Therapeutics. https:\/\/adisinsight.springer.com\/drugs\/800027596"},{"key":"e_1_3_2_69_1","first-page":"1","article-title":"New perspectives in oral peptide delivery","author":"Zizzari AT","year":"2021","unstructured":"Zizzari AT , PliatsikaD , GallFM , FischerT , RiedlR. New perspectives in oral peptide delivery. Drug Discov. Today1\u20139 (2021).","journal-title":"Drug Discov. Today"},{"key":"e_1_3_2_70_1","unstructured":"Adis Insight . Transbuccal insulin \u2013 MidaSol. https:\/\/adisinsight.springer.com\/drugs\/800035425"},{"key":"e_1_3_2_71_1","volume-title":"Microbiology for the Healthcare Professional (2nd Edition).","author":"VanMeter KC","year":"2015","unstructured":"VanMeter KC , HubertJR. Microbiology for the Healthcare Professional (2nd Edition).Elsevier Health Sciences, Amsterdam, The Netherlands (2015)."},{"key":"e_1_3_2_72_1","unstructured":"Republic of Lebanon - Ministry of Public Health . Lebanon National Drugs Database. www.moph.gov.lb\/en\/Pages\/3\/3010\/pharmaceuticals#\/en\/Drugs\/index\/3\/3974\/lebanon-national-drugs-database"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2013.0312"},{"issue":"2","key":"e_1_3_2_74_1","first-page":"143","article-title":"Prevalence of primary non-adherence with insulin and barriers to insulin initiation in patients with Type 2 diabetes mellitus - an exploratory study in a tertiary care teaching public hospital","volume":"16","author":"Sharma SK","year":"2020","unstructured":"Sharma SK , KantR , KalraS , BishnoiR. Prevalence of primary non-adherence with insulin and barriers to insulin initiation in patients with Type 2 diabetes mellitus - an exploratory study in a tertiary care teaching public hospital. Eur. Endocrinol.16(2), 143\u2013147 (2020).","journal-title":"Eur. Endocrinol."},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13454"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1807"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1080\/17435390802398309"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1207"},{"key":"e_1_3_2_79_1","volume-title":"Endotext.","author":"Donner T","year":"2019","unstructured":"Donner T . Insulin\u2013pharmacology, therapeutic regimens and principles of intensive insulin therapy. In: Endotext.MDText.com, Inc., MA, USA (2019)."},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1177\/1932296817691303"}],"container-title":["Therapeutic Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/tde-2021-0021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T22:43:58Z","timestamp":1715985838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/tde-2021-0021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.4155\/tde-2021-0021"],"URL":"https:\/\/doi.org\/10.4155\/tde-2021-0021","relation":{},"ISSN":["2041-5990","2041-6008"],"issn-type":[{"value":"2041-5990","type":"print"},{"value":"2041-6008","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=itde20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=itde20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-03-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}